Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer

Sep 18, 2017

Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference

Sep 6, 2017

Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window

Aug 22, 2017

Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance

Aug 14, 2017

Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients

Aug 8, 2017

Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance

Aug 3, 2017

Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors

Aug 1, 2017

Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference

Jun 6, 2017

Cellectar Biosciences to Present at the LD Micro Invitational Conference

May 30, 2017

Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings

May 18, 2017
    • 1...
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • ...36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A